Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8409065 | 0.87 | SLC6A4 (0.50) | SMN1; SMN2JAK2ZAP70CCNB2CDK1 | |
| SCHEMBL7927301 | 0.84 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1HPGDHTTMEN1 | |
| SCHEMBL1119150 | 0.79 | JAK2 (0.57) | SMN1; SMN2MEN1KMT2AKDM4EJAK2 | |
| SCHEMBL16632374 | 0.78 | PTGER1 (0.48) | MEN1KMT2AJAK2ZAP70CCNB2 | |
| SCHEMBL20535668 | 0.78 | TACR2 (0.54) | SMN1; SMN2ALDH1A1HPGDHTTMEN1 | |
| SCHEMBL454383 | 0.77 | ERN1 (0.48) | SMN1; SMN2ALDH1A1HPGDHTTMEN1 | |
| SCHEMBL30933896 | 0.77 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1HPGDHTTKDM4E | |
| SCHEMBL18661703 | 0.76 | CHRM1 (0.49) | SMN1; SMN2KDM4EGAAPTGER1 | |
| SCHEMBL30038603 | 0.76 | CHRM1 (0.49) | SMN1; SMN2KDM4EGAAPTGER1 | |
| SCHEMBL4754158 | 0.76 | L3MBTL1 (0.51) | SMN1; SMN2ALDH1A1HPGDHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350162-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3350162-B1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | JANSSEN PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| CN-108473422-B | Monosubstituted or disubstituted indole derivatives as inhibitors of dengue virus replication | 杨森制药公司 | 2021-06-15 | — | — | CN | disclosed |
| US-10765662-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10765662-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20180256545-A1 | Mono- or Di-Substituted Indole Derivatives As Dengue Viral Replication Inhibitors | Janssen Pharmaceuticals, Inc. (US) | 2018-09-13 | — | — | US | disclosed |
| EP-3350162-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046255-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046255-A1 | MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS | Janssen Pharmaceuticals, Inc. (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10765662-B2 | Mono- or di-substituted indole derivatives as dengue viral replication inhibitors | IDO1, IDO2, IRF3 | SMN1; SMN2 4695/4885ALDH1A1 2512/4885HPGD 1358/4885 |
| US-20180256545-A1 | Mono- or Di-Substituted Indole Derivatives As Dengue Viral Replication Inhibitors | IDO1, IDO2, IRF3 | SMN1; SMN2 4695/4885ALDH1A1 2512/4885HPGD 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.